Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic

Journal of Biomolecular Structure and Dynamics

Volumn 30, Issue 5, 2012, Pages 594-606

  Banappagari, Sashikanth ^a   Corti, Miriam ^b   Pincus, Seth ^b   Satyanarayanajois, Seetharama ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

EGFR; HER2; Homology modeling; Pathhunter assay; Peptidomimetic; Protein protein interactions; Surface plasmon resonance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; H ARGININE [3 AMINO 3 (NAPTHYL)PROPIONIC ACID]PHENYL HYDROXIDE; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING KINETICS; CANCER CELL CULTURE; CRYSTAL STRUCTURE; DIMERIZATION; DOSE RESPONSE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME ASSAY; ENZYME IMMOBILIZATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

CELL LINE, TUMOR; CIRCULAR DICHROISM; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; OLIGOPEPTIDES; PEPTIDOMIMETICS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

EID: 84865651620     PISSN: 07391102     EISSN: 15380254     Source Type: Journal    
DOI: 10.1080/07391102.2012.687525     Document Type: Article

References (54)

1. Ahn, E.R., & Vogel, C.L. (2011). Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Research and Treatment, 131, 371-383.
2. Allen, S., Garrett, J.T., Rawale, S.V., Jones, A.L., Philips, G., Forni, G., Kaumaya, T.P. (2007). Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. Journal of Immunology, 179, 472-482.
3. Arcangeli, C., Cantale, C., Galeffi, P., Gianese, G., Paparcone, R., & Rosato, V. (2008). Understanding structural/functional properties of immunoconjugates for cancer therapy by computational approaches. Journal of Biomolecular Structure and Dynamics, 26, 35-48.
4. Arnold, K., Bordoli, L., Kopp, J., & Schwede, T. (2010). The SWISS-MODEL workspace: A web-based environment for protein structure homology modeling. Bioinformatics, 22, 195-201.
5. Arpino, G., Gutierrez, C., Weiss, H., Rimawi, M., Massarweh, S., Bharwani, L., Schiff, R. (2007). Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. Journal of the National Cancer Institute, 99, 694-705.
6. Bahadur, R.P., Chakrabarti, P., Rodier, F., & Janin, J. (2004). A dissection of specific and non-specific protein-protein interfaces. Journal ofMolecular Biology, 336, 943-955.
7. Banappagari, S., Ronald, S., & Satyanarayanajois, S.D. (2011). Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines. MedChem-Comm, 2, 752-759.
8. Banappagari, S., Satyanarayanajois, S.D., & Ronald, S. (2010). A conformationally constrained peptidomimetic binds to extracellular region of HER2 protein. Journal of Biomolecular Structure and Dynamics, 28, 289-308.
9. Baselga, J., & Swain, S. (2009). Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nature Reviews. Cancer, 9, 463-475.
10. Berezov, A., Chen, J., Liu, Q., Zhang, H.T., Greene, M.I., & Murali, R. (2002). Disabling receptor ensembles with rationally designed interface peptidomimetics. Journal of Biological Chemistry, 277, 28330-28339.
11. Berezov, A., Zhang, H.T., Greene, M.I., & Murali, R. (2001). Disabling ErbB receptors with rationally designed exocyclic mimetics of antibodies: Structure-function analysis. Journal of Medicinal Chemistry, 44, 2565-2574.
12. Burgess, A.W., Cho, H.S., Eigenbrot, C., Ferguson, K.M., Garrett, T.P., Leahy, D.J., Yokoyama, S. (2003). An open-and-shut case? Recent insights into the activation of EGF/ ErbB receptors Molecular Cell, 12, 541-552.
13. Chang, J.C. (2007). HER2 inhibition: From discovery to clinical practice. Clinical Cancer Research, 13, 1-3.
14. Chen, C.Y.C. (2009). Weighted equation and rules-a novel concept for evaluating protein-ligand interaction. Journal of Biomolecular Structure and Dynamics, 3, 271-282.
15. Chen, V.B., Arendall, W.B.III, Headd, J.J., Keedy, D.A., Immor-mino, R.M., Kapral, G.J., Richardson, D.C. (2010). Mol-Probity: All-atom structure validation for macromolecular crystallography. Acta Crystallographica, D66, 12-21.
16. Chene, P. (2006). Drugs targeting protein-protein interactions. ChemMedChem, 1, 400-411.
17. Cho, H.S., & Leahy, D.J. (2002). Structure of the extracellular region of HER3 reveals an interdomain tether. Science, 297, 1330-1333.
18. Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelll, S.B., Denney, D.W., & Leahy, D.J. (2003). Structure of the extracellular region of HER2 alone and in complex with herceptin Fab. Nature, 421, 756-760.
19. Dakappagari, N.K., Lunte, K.D., Rawale, S., Steele, J.T., Allen, S.D., Phillips, G., Kaumaya, T.P. (2005). Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. Journal of Biological Chemistry, 280, 54-63.
20. Dawson, J.P., Berger, M.B., Lin, C.C., Schlessinger, J., Lemmon, M.A., & Ferguson, K.M. (2005). Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Molecular and Cellular Biology, 25, 7734-7742.
21. Drozdov-Tikhomirov, L.N., Linde, D.M., Poroikov, V.V., Alexandrov, A.A., & Skurida, G.I. (2001). Molecular mechanisms of protein-protein recognition: Whether the surface placed charged residues determine the recognition process? Journal of Biomolecular Structure and Dynamics, 19, 279-284.
22. Ferguson, K.M. (2008). Structure-based view of epidermal growth factor receptor regulation. Annual Review of Biophysics, 37, 353-373.
23. Fisher, R.D., Ultsch, M., Lingel, A., Schaefer, G., Shao, L., Birtalan, S., Eigenbrot, C. (2010). Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine. Journal of Molecular Biology, 402, 217-229.
24. Franklin, M.C., Carey, K.D., Vajdos, F.F., Leahy, D.J., De Vos, A.M., & Sliwkowski, M.X. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell, 5, 317-328.
25. Fuller, J.C., Burgoyne, N.J., & Jackson, R.M. (2009). Predicting druggable binding sites at the protein-protein interface. Drug Discovery Today, 14, 155-161.
26. Gijsen, M., King, P., Perera, T., Parker, P.J., Harris, A.L., Larijani, B., & Kong, A. (2010). HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biology, 8, e1000563.
27. Huang, H.J., Lee, K.J., Yu, H.W., Chen, C.Y., Hsu, C.H., Chen, H.Y., Chen, C.Y.C. (2010). Structure-based and ligand-based drug design for HER 2 receptor. Journal of Biomo-lecular Structure and Dynamics, 28, 23-37.
28. Hynes, E.N., & Lane, H.A. (2005). ERBB receptors and cancer: The complexity of targeted inhibitors. Nature Reviews, Cancer, 5, 341-354.
29. Khan, S.H., Ahmad, F., Ahmad, N., Flynn, D.C., & Kumar, R. (2011). Protein-Protein interactions: Principles, techniques, and their potential role in new drug development. Journal of Biomolecular Structure and Dynamics, 28, 929-938.
30. Komolov, K.E., & Koch, K.W. (2010). Application of surface plasmon resonance spectroscopy to study G-protein coupled receptor signaling in surface plasmon resonance. In (Chapter 17) N.J. Moi & M.J.E. Fischer (Eds.), Methods in molecular biology (p. 627). New York, NY: Springer Science.
31. Kumagai, T., Katsumata, M., Hasegawa, A., Furuuchi, K., Funakoshi, T., Kawase, I., & Greene, M.I. (2003). Role of extracellular subdomains of p185c-neu and epidermal growth factor receptor in ligand-independent association and transactivation. Proceedings of the National Academy ofSciences USA, 100, 9220-9225.
32. Landgraf, R. (2007). HER2(ERBB2):functional diversity from structurally conserved building blocks. Breast Cancer Research, 9, 202-209.
33. Lee-Hoeflich, S.T., Crocker, L., Yao, E., Pham, T., Munroe, X., Heoflich, K.P., Stern, H. (2008). A central role of HER3 in HER2 amplified breast cancer: Implications for targeting therapy. Cancer Research, 68, 5878-5887.
34. Levitzki, A., & Gazit, A. (1995). Tyrosine kinase inhibition: An approach to drug development. Science, 267, 1782-1788.
35. Liang, S., Li, W., Xiao, L., Wang, J., & Lai, L. (2000). Grafting of protein-protein interaction epitope. Journal of Bio-molecular Structure and Dynamics, 17, 821-828.
36. Lombardi, A., Gianese, G., Arcangeli, C., Galeffi, P., & Sperandei, M. (2011). Bacterial cytoplasm production of an EGFP-labeled single-chain Fv antibody specific for the HER2 human receptor. Journal of Biomolecular Structure and Dynamics, 29, 425-439.
37. Lu, C., Mi, L.Z., Grey, M.J., Zhu, J., Graef, E., Yokoyama, S., & Springer, T.A. (2010). Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Molecular and Cellular Biology, 30, 5432-5443.
38. Molina, M.A., Codony-Servat, J., Albancell, J., Rojo, F., Arribas, J., & Baselga, J. (2001). Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Research, 61, 4744-4749.
39. Moreira, I.S., Fernandes, P.A., & Ramos, M.J. (2007). Hot spots - a review of the protein-protein interface determinant amino acid residues. Proteins, 68, 803-812.
40. Myszka, D.G. (2000). Kinetic, equilibrium, and thermodynamic analysis of macromolecular interactions with BIACORE. Methods in Enzymology, 323, 325-340.
41. Nahta, R., & Esteva, F.J. (2003). HER2 targeted therapy: Les-sions learned and future directions. Clinical Cancer Research, 9, 5078-5084.
42. Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.H., Yokoyama, S. (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 110, 775-787.
43. Reichmann, D., Rahat, O., Cohen, M., Neuvirth, H., & Schreiber, G. (2007). The molecular architecture of protein-protein binding sites. Current Opinion in Structural Biology, 17, 67-76.
44. Ryan, D.P., & Mathews, J.M. (2005). Protein-protein interactions in human disease. Current Opinion in Structural Biology, 15, 441-446.
45. Satyanarayanajois, S.D., Villalba, S., Jianchao, L., & Lin, G.M. (2009). Design, synthesis, and docking studies of pepti-domimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines. Chemical Biology and Drug Design, 74, 246-257.
46. Saxon, M.L., & Lee, D.C. (1999). Mutagenesis reveals a role for epidermal growth factor receptor extracellular subdomain IV in ligand binding. Journal of Biological Chemistry, 274, 283 56-283 62.
47. Shankaran, H., Wiley, H.S., & Resat, H. (2006). Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. Biophysical Journal, 90, 3993-4009.
48. Sperandio, O., Reynes, C.H., Camproux, A.C., & Villoutriex, B. O. (2010). Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discovery Today, 15, 220-229.
49. Tao, R.H., & Maruyama, I.N. (2008). All EGFR (ErbB) receptors have preformed homo-and heterodimeric structures in living cells. Journal of Cell Science, 121, 3207-3217.
50. Venyaminov, S.U., & Yang, J.T. (1996). Determination of protein secondary structure in circular dichroism and the conformational analysis of biomolecules. In G.D. Fasman (Ed.), Circular dichroism and the conformational analysis of biomolecules (pp. 69-108). New York, NY: Plenum Press.
51. Wells, J.A., & McClendon, C.L. (2007). Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature, 450, 1001-1009.
52. Yang, R.Y.C., Yang, K.S., Pike, L.J., Garland, R., & Marshall, G.R. (2010). Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors. Chemical Biology and Drug Design, 76, 1-9.
53. Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Chen, Y.A. (2009). Lipid G protein-coupled receptor ligand identification using P-arrestin PathHunter™ assay. Journal of Biological Chemistry, 284, 12328-12338.
54. Yuzawa, S., Opatowsky, Y., Zhang, Z., Mandiyan, V., Lax, I., & Schlessinger, J. (2007). Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell, 130, 323-334.